WO2007021721A2 - Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas - Google Patents
Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas Download PDFInfo
- Publication number
- WO2007021721A2 WO2007021721A2 PCT/US2006/030993 US2006030993W WO2007021721A2 WO 2007021721 A2 WO2007021721 A2 WO 2007021721A2 US 2006030993 W US2006030993 W US 2006030993W WO 2007021721 A2 WO2007021721 A2 WO 2007021721A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- salt
- substituted
- nhac
- para
- Prior art date
Links
- SLFZKCPNPDDSFA-UHFFFAOYSA-N CNC(c(cc1)ccc1-c1ccccc1)=O Chemical compound CNC(c(cc1)ccc1-c1ccccc1)=O SLFZKCPNPDDSFA-UHFFFAOYSA-N 0.000 description 1
- JVXXKQIRGQDWOJ-UHFFFAOYSA-N NC(c1ccc(cccc2)c2c1)=O Chemical compound NC(c1ccc(cccc2)c2c1)=O JVXXKQIRGQDWOJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)
Definitions
- the present invention relates generally to compounds, compositions and methods for the diagnosis and therapy of diseases in warm-blooded animals (e.g., in humans) involving infections with and colonization by Pseudomonas bacteria, including Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis.
- the invention relates more particularly to the use of one or more compounds selective for binding PA-IL and/or PA-IIL lectins of Pseudomonas bacteria. These compounds are useful for diagnosis and/or therapeutic intervention of the colonization of Pseudomonas bacteria, or may be linked to an agent(s) to target and effectively arrest or kill Pseudomonas bacteria.
- Pseudomonas infections occur in a variety of medical conditions and can be life threatening.
- Pseudomonas is an opportunistic bacterium. Examples of individuals at risk include cystic fibrosis patients, burn patients, and patients on ventilators. Cystic fibrosis is described below as a representative example of a medical condition which can involve infection with Pseudomonas bacteria.
- Cystic Fibrosis is the most common lethal genetic disease among the Caucasian population. CF is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), which acts as a chloride channel. The genetic mutations of CFTR which alter ion movements also affect the N-glycosylation of CFTR as well as other cell surface molecules. All of the exocrine glands of the patients are affected; however, the lungs are the primary site of morbidity and mortality. The general change in glycosylation is associated with an increase in infectivity by Pseudomonas aeruginosa. The salivary and respiratory mucins from CF patients also contain altered glycosylation patterns.
- CFTR cystic fibrosis transmembrane conductance regulator
- this invention provides compounds, compositions and methods for utilizing both the PA-IIL and PA-IL lectins, or either one alone, expressed by Pseudomonas bacteria for the detection of Pseudomonas bacteria and the diagnosis and therapy of disease involving Pseudomonas bacteria, including human disease.
- compounds of the present invention that have high affinity binding to the PA-IIL lectin, the PA-IL lectin or both lectins from P. aeruginosa will have a beneficial therapeutic effect on CF patients.
- these compounds may be administered in combination therapy with antibiotics or may be conjugated, for example, with antibiotics to increase the efficacy and lower the dose, thereby avoiding well known deleterious side effects of many antibiotics.
- antibiotics may be administered in combination therapy with antibiotics or may be conjugated, for example, with antibiotics to increase the efficacy and lower the dose, thereby avoiding well known deleterious side effects of many antibiotics.
- binding sites are crucial for the colonization and pathogenicity of the bacterium, mutations in this target to become resistant to this conjugate therapy should result in non-pathogenic forms of the bacteria.
- One embodiment of the present invention provides a compound or physiologically acceptable salt thereof, having the formula:
- R 1 independently selected from OH, NHAc, 6' sulfated GIcNAc, 6' carboxylated GIcNAc, GaINAc, galactose linked by an O glycosidic bond, a C glycosidic bond or an S glycosidic bond, thiodigalactoside, 6' sulfated galactose and 6' carboxylated galactose, with the proviso that three of the four R 1 are independently selected from OH and NHAc and one R 1 is not OH or NHAc;
- R 2 H, a fucose, a galactose, an arabinose, a fructose, a mannose, cyclohexane, substituted cyclohexane, tetrahydropyran, substituted tetrahydropyran, piperidine, substituted piperidine, a polyol or substituted polyol;
- R 3 (CH 2 )p, NH 2 , — CH 2 -OH, — CH 2 -(NH- ⁇ X or where m, n and q are independently
- X is NH-C 1 -C 8 alkyl, C 3 -C 8 cydoalkyl, substituted C 3 -C 8 cycloalkyl, C 1 -C 8 alkyl, C 6 -Ci 4 aryl, substituted C 6 -C 14 aryl, C 1 -C 14 heteroaryl, substituted C 1 -C 14 heteroaryl, non-aryl C 1 -C 14 heterocycle or substituted non-aryl C 1 -C 14 heterocycle, NHCH 2 Ph, N(CH 2 Ph) 2 , NHSO 3 Na, NHCO-C 6 H 4 -COOH (ortho), NHCOPh, NHCO-C 6 H 4 -CI (para), NHCO-C 6 H 4 -OMe (para), NHCO-C 6 H 4 -NO 2 (para), NHCO-C 6 H 4 -Ph (para), NHCO-C
- N(CH 2 Ph)COPh NHCOCH 2 CH 2 Ph, NHCOCHPh 2 , NHCOMe, NHCO(CyCIo-C 6 H 11 ), NHSO 2 -C 6 H 4 -Me (para), NHCONHEt, NHCONHPh, NHCOOCH 2 -C 6 H 4 -NO 2 (para), NHCOOCH 2 (2-naphthyl), or NHCOOCH 2 Ph;
- R 4 H, NHAc, -O-Lactose, substituted -O-Lactose, -O-Lactosamine, substituted -O-Lactosamine, NHAc substituted with N-glycolyl, polyethylene glycol or substituted polyethylene glycol; and
- R 5 H, NHAc, or NHAc substituted with N-glycolyl.
- a compound or salt thereof of the present invention may be in combination with a pharmaceutically acceptable carrier or diluent.
- the present invention provides a conjugate comprising a therapeutic agent linked to a compound as set forth above.
- Another embodiment of the present invention provides a method of inhibiting Pseudomonas bacteria infection in a warm-blooded animal comprising administering to the animal in an amount effective to inhibit one or more lectins of the bacteria a compound comprising a compound or physiologically acceptable salt thereof, having the formula:
- R 1 independently selected from OH, NHAc, 6' sulfated GIcNAc, 6' carboxylated GIcNAc, GaINAc, galactose linked by an O glycosidic bond, a C glycosidic bond or an S glycosidic bond, thiodigalactoside, 6' sulfated galactose and 6' carboxylated galactose, with the proviso that three of the four R 1 are independently selected from OH and NHAc and one R 1 is not OH or NHAc;
- R 2 H, a fucose, a galactose, an arabinose, a fructose, a mannose, cyclohexane, substituted cyclohexane, tetrahydropyran, substituted tetrahydropyran, piperidine, substituted piperidine, a polyol or substituted polyol;
- R 3 (CH 2 )p, NH 2 , — CH 2 -OH, — CH 2 -( NH ⁇ X or
- m, n and q are independently selected from 0-1, p is 1-20, Z is N, O or S, and X is NH-Ci-C 8 alkyl, C 3 -C 8 cycloalkyl, substituted C 3 -C 8 cycloalkyl, C x -C 8 alkyl, C 6 -C 14 aryl, substituted C 6 -Ci 4 aryl, Ci-Ci 4 heteroaryl, substituted C x -Ci 4 heteroaryl, non-aryl Ci-C 14 heterocycle or substituted non-aryl C x -Ci 4 heterocycle, NHCH 2 Ph, N(CH 2 Ph) 2 , NHSO 3 Na, NHCO-C 6 H 4 -COOH (ortho), NHCOPh, NHCO-C 6 H 4 -CI (para), NHCO-C 6 H 4 -OMe (para), NHCO-C 6 H 4 -NO 2 (para), NHCO-C 6 H 4 -
- the present invention provides a method of detecting Pseudomonas bacteria comprising contacting a sample with a diagnostic agent linked to a compound comprising a compound as set forth above, under conditions sufficient for the compound to bind to the bacteria or its lectin products if present in the sample; and detecting the agent present in the sample, wherein the presence of agent in the sample is indicative of the presence of Pseudomonas bacteria.
- the present invention provides a method of immobilizing Pseudomonas bacteria on a solid support comprising contacting, under conditions sufficient for binding, a sample containing Pseudomonas bacteria with a compound comprising a compound as set forth above that is immobilized on a solid support; and separating the sample from the solid support.
- the compounds and conjugates described herein may be used in the preparation of a medicament for the inhibition of Pseudomonas bacteria.
- Figure 1 is a diagram illustrating the synthesis of a glycomimetic compound.
- Figure 2A is a diagram illustrating the synthesis of a glycomimetic compound containing a linker arm.
- Figure 2B is a diagram illustrating the conjugation of the compound of Figure 2A to the antibiotic tobramycin.
- Figures 3A and 3B are diagrams illustrating the synthesis of glycomimetic compounds.
- Figure 4 depicts the structures of three of the compounds (Compound A, Compound B, and Glycomimetic 1) used in one or more of the lectin assays described herein.
- Figure 5 graphically illustrates the inhibition of PA-IL lectin by
- PA-IL lectin is a galactose-binding lectin and is inhibited by galactose, Melibiose (Gal ⁇ l-6Gal), and Glycomimetic 1; but not by fucose, Compound A or Compound B.
- Figure 6 graphically illustrates inhibition of the PA-IIL Lectin.
- the fucose binding lectin, PA-IIL is inhibited by fucose, Compound A and Glycomimetic 1; but not by galactose.
- Figure 7 shows the determination of IC 50 value for Glycomimetic 1 for inhibition of PA-IL.
- Glycomimetic 1 inhibits the galactose-binding lectin, PA-IL about 4 to 5 times better than galactose; whereas, fucose is inactive.
- Figure 8 shows the IC 50 determination of Glycomimetic 1 for inhibition of PA-IIL.
- Glycomimetic 1 inhibits the fucose-binding lectin, PAUL about 4 to 5 times better than fucose; while galactose is inactive.
- Figure 9 illustrates the inhibition of PA-IIL binding to human epithelial cells. Human buccal epithelial cells are incubated with biotinylated PA-IIL lectin followed by detection of bound lectin with fluorescein-labeled streptavidin. Fluorescently labeled cells are quantified by fluorescent-activated cell sorting (B). Incubation of the PA-IIL lectin with fucose (D) or Glycomimetic 1 (E and F) inhibits binding to the cell surface. Galactose (C) has no effect.
- the present invention provides compounds and compositions that bind Pseudomonas bacterial lectins (e.g., P. aeruginosa lectins) and may be used in the diagnosis and therapy of disease.
- Pseudomonas bacterial lectins e.g., P. aeruginosa lectins
- Glycomimetic compound refers to a compound (including physiologically acceptable salts thereof) that has high affinity for the PA-IL lectin, PA-IIL lectin or both lectins from Pseudomonas bacteria.
- Embodiments of the structures of the Glycomimetic compounds of this invention have the formula:
- R 1 independently selected from OH, NHAc, 6' sulfated GIcNAc, 6' carboxylated GIcNAc, GaINAc, galactose linked by an O glycosidic bond, a C glycosidic bond or an S glycosidic bond, thiodigalactoside, 6' sulfated galactose and 6' carboxylated galactose;
- R 2 H, a fucose, a galactose, an arabinose, a fructose, a mannose, cyclohexane, substituted cyclohexane, tetrahydropyran, substituted tetrahydropyran, piperidine, substituted piperidine, a polyol or substituted polyol;
- R 3 (CH 2 )p, NH 2 , — CH 2 -OH, — CH 2 -( NH ⁇ -X or
- m, n and q are independently selected from 0-1, p is 1-20, Z is N, O or S, and X is NH-C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, substituted C 3 -C 8 cycloalkyl, Ci-C 8 alkyl,
- R 4 H, NHAc, -0-Lactose, substituted -O-Lactose, -O-Lactosamine, substituted -O-Lactosamine, NHAc substituted with N-glycolyl, polyethylene glycol or substituted polyethylene glycol;
- R 5 H, NHAc, or NHAc substituted with N-glycolyl. All compounds (or conjugates thereof) useful in the present invention include physiologically acceptable salts thereof.
- Glycomimetic compounds of the present invention include the formula set forth above with substituents R ⁇ R 5 .
- substituent options i.e., atom or group
- R ⁇ -R 5 possesses a "-" this is to indicate the point of attachment (to a ring for R la , R lb , R lc and R 3 -R 5 , to CH 2 for R ld , and to O for R 2 ), and does not represent CH 2 or CH 3 .
- the oxygen may be in an alpha 1-3 linkage or a beta 1-3 linkage.
- a line to which no group is depicted represents the bond that attaches the substituent to the structure depicted by the general formula.
- a "C 6 -Ci 4 aryl” refers to an aromatic substituent with six to fourteen carbon atoms in one or multiple rings which may be separated by a bond or an alkyl group or be fused.
- a "Ci-C 14 heteroaryl” is similar to a "C 6 -Ci 4 aryl,” except the aromatic substituent possesses at least one heteroatom (such as N, O or S) in place of a ring carbon. Examples of aryls and heteroaryls include phenyl, naphthyl, diphenyl, pyridinyl and pyrimidinyl.
- R 1 is composed of R la , R lb , R lc and R ld , as depicted in the above formula.
- R la is attached at carbon position 2.
- R lb is attached at carbon position 3.
- R lc is attached at carbon position 4.
- R ld is attached at carbon position 6, which in turn is attached at carbon position 5.
- R 1 substituents examples include GaINAc, 6' sulfated GIcNAc and 6' carboxylated GIcNAc.
- the abbreviation "GIcNAc” represents N-Acetylglucosamine and "GaINAc” represents N-Acetylgalactosamine.
- Other R 1 substituents are OH, NHAc, galactose, thiodigalactoside, 6' sulfated galactose and 6' carboxylated galactose.
- Galactose is linked by an O glycosidic bond, a C glycosidic bond or an S glycosidic bond.
- R 1 as set forth with the above formula is galactose, 6' sulfated galactose or 6' carboxylated galactose
- R 1 in an embodiment is attached by an alpha 1-3 linkage, but the linkage may be beta.
- only one of the four R 1 is other than OH or NHAc (i.e., selected from one of the R 1 substituents listed other than OH or NHAc).
- R 2 substituents include monosaccharides, such as fucose, galactose, arabinose, fructose or mannose.
- the monosaccharides possess a D- and an L- form.
- Such monosaccharides include L-fucose,
- a monosaccharide of R 2 may be replaced with a mimic of the monosaccharide.
- a monosaccharide ring may be replaced with a cyclohexane, substituted cyclohexane, tetrahydropyran, substituted tetrahydropyran, piperidine, substituted piperidine, a polyol or substituted polyol.
- substituents may be added to a ring as replacement for, or in addition to, existing substituents or both.
- one or more hydroxyl groups may be replaced with alkoxy groups (such as methoxy, ethoxy, propoxy, etc.), halides (such as fluorine, chlorine, etc.), esters and amides.
- one or more hydrogens of cyclohexane, tetrahydropyran or piperidine may be replaced with such groups (alkoxy, halide, ester and amide) to produce a substituted cyclohexane, substituted tetrahydropyran or substituted piperidine, respectively.
- R 3 substituents include (CH 2 ) P where p is 1-20,
- X is NH-C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, substituted C 3 -C 8 cycloalkyl, Ci-C 8 alkyl, C 6 -Ci 4 aryl, substituted C 6 -Ci 4 aryl, C x -Ci 4 heteroaryl, substituted C x -Ci 4 heteroaryl, non-aryl Ci-Ci 4 heterocycle or substituted non-aryl Ci-Ci 4 heterocycle.
- C 1 -C 8 alkyl refers to a saturated hydrocarbon which may be straight chained or branched. Examples are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and t-butyl.
- C 6 -Ci 4 aryl and “Ci-C 14 heteroaryl” are as defined above. Examples are provided above.
- a "substituted C 6 -Ci 4 aryl” is a C 6 -Ci 4 aryl wherein at least one ring hydrogen is replaced with one or more atoms other than hydrogen.
- a “substituted CrC 14 heteroaryl” is a Ci-Ci 4 heteroaryl wherein at least one ring hydrogen or hydrogen attached to a heteroatom is replaced with one or more atoms other than hydrogen. Such atoms include carbon, oxygen, nitrogen, sulfur and halogen.
- a “non-aryl Ci-C 14 heterocycle” refers to a non-aromatic substituent with one to fourteen carbon atoms (with at least one heteroatom) in one or multiple rings which may be separated by a bond or fused. The third atom of a three member ring may be provided by the carbon to which R 3 is attached. Examples include piperidine, piperazine, pyrrolidine, and their oxygen and sulfur equivalents.
- a "substituted non-aryl C f Ci 4 heterocycle” is a non-aryl Ci-Ci 4 heterocycle wherein at least one ring hydrogen or hydrogen attached to a heteroatom is replaced with one or more atoms other than hydrogen. Such atoms include carbon, oxygen, nitrogen, sulfur and halogen.
- R 3 examples include NHCOPh, NHCO-C 6 H 4 -CI (para), NHCO-C 6 H 4 -OMe (para), NHCO-C 6 H 4 -NO 2 (para), NHCO-C 6 H 4 -Ph (para), NHCO-C 6 H 3 (OMe) 2 (meta, para), NHC0(2-naphthyl), NHCO-C 6 H 4 -OCH 2 Ph (para), N(CH 2 Ph)COPh, NHCOCH 2 CH 2 Ph, NHCOCHPh 2 , NHCOMe, NHCO(cyclo-C 6 Hu), NHSO 2 -C 6 H 4 -Me (para), NHCONHEt, NHCONHPh, NHCOOCH 2 -C 6 H 4 -NO 2 (para), NHCOOCH 2 (2-naphthyl), or NHCOOCH 2 Ph.
- the abbreviation "Ph” represents "phenyl”.
- R 4 substituents include H, NHAc, and NHAc substituted with N-glycolyl. It also includes -O-Lactose, substituted -O-Lactose, -O-Lactosamine, substituted -O-Lactosamine, polyethylene glycol and substituted polyethylene glycol.
- R 5 substituents include H, NHAc, and NHAc substituted with N-glycolyl.
- non-monosaccharide, ringed substituents examples include:
- a diagnostic or therapeutic agent such as a drug to a Glycomirnetic compound
- link a diagnostic or therapeutic agent such as a drug to a Glycomirnetic compound
- a therapeutic agent refers to any bioactive agent intended for administration to a warm-blooded animal (e.g., a mammal such as a human) to prevent or treat a disease or other undesirable condition or to enhance the success of therapies.
- Therapeutic agents include antibiotics, hormones, growth factors, proteins, peptides, genes, non-viral vectors and other compounds.
- Glycomimetic compounds as described herein may be present within a pharmaceutical composition.
- a pharmaceutical composition comprises one or more Glycomimetic compounds in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.
- Such compositions may comprise buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide) and/or preservatives.
- buffers e.g., neutral buffered saline or phosphate buffered saline
- carbohydrates e.g., glucose, mannose, sucrose or dextrans
- mannitol e.g., proteins, polypeptides or amino acids
- glycine
- compositions of the present invention may be formulated as a lyophilizate.
- Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, aerosol, topical, oral, nasal, intravenous, intracranial, intraperitoneal, subcutaneous, or intramuscular administration.
- a pharmaceutical composition may also, or alternatively, contain one or more active agents, such as drugs (e.g., antibiotics), which may be linked to a Glycomimetic compound or may be free within the composition.
- active agents such as drugs (e.g., antibiotics)
- drugs e.g., antibiotics
- the attachment of an agent to a Glycomimetic compound may be covalent or noncovalent.
- An example of an active agent is tobramycin. Tobramycin alone has typically been administered intravenously or by inhalation.
- compositions described herein may be administered as part of a sustained release formulation (i.e., a formulation such as a capsule or sponge that effects a slow release of modulating agent following administration).
- a sustained release formulation i.e., a formulation such as a capsule or sponge that effects a slow release of modulating agent following administration.
- Such formulations may generally be prepared using well known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site.
- Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of modulating agent release.
- the amount of Glycomimetic compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.
- Glycomimetic compounds are generally present within a pharmaceutical composition in a therapeutically effective amount.
- a therapeutically effective amount is an amount that results in a discernible patient benefit, such as a measured or observed response of a condition associated with Pseudomonas infection.
- Giycomimetic compounds described herein may be used for achieving diagnostic and/or therapeutic results in disease (e.g., human disease) involving infection by Pseudomonas (e.g., P. aeruginosa) bacteria.
- disease e.g., human disease
- Pseudomonas e.g., P. aeruginosa
- Such diagnostic and/or therapeutic results may be achieved in vitro and/or in vivo in an animal, preferably in a mammal such as a human, provided that Pseudomonas (e.g., P. aeruginosa) or its products are ultimately contacted with a Glycomimetic compound, in an amount and for a time sufficient to achieve a discernable diagnostic or therapeutic result.
- a therapeutic result would relate, for example, to the prevention of lung infections.
- therapeutic results would be associated with the inhibiting of Pseudomonas (such as P. aeruginosa) or its products (where inhibiting includes, for example, arresting the growth of or killing the bacteria or preventing colonization by the bacteria).
- therapy or therapeutic results includes treatment or prevention.
- Glycomimetic compounds of the present invention may be administered in a manner appropriate to the disease to be treated or prevented. Appropriate dosages and a suitable duration and frequency of administration may be determined by such factors as the condition of the patient, the type and severity of the patient's disease and the method of administration. In general, an appropriate dosage and treatment regimen provides the modulating agent(s) in an amount sufficient to provide treatment and/or prophylactic benefit.
- a Glycomimetic compound may be administered at a dosage ranging from 0.001 to 1000 mg/kg body weight (more typically 0.01 to 1000 mg/kg), on a regimen of single or multiple daily doses. Appropriate dosages may generally be determined using experimental models and/or clinical trials.
- Glycomimetic compounds described herein may be administered in combination (i.e., simultaneously or sequentially) with another anti-bacterial compound.
- a Glycomimetic compound may be administered in combination with tobramycin.
- Glycomimetic compounds may also be used to target substances to Pseudomonas bacteria, e.g., P. aeruginosa.
- Such substances include therapeutic agents and diagnostic agents.
- Therapeutic agents may be a molecule, virus, viral component, cell, cell component or any other substance that can be demonstrated to modify the properties of a target cell so as to provide a benefit for treating or preventing a disorder or regulating the physiology of a patient.
- a therapeutic agent may also be a drug or a prodrug that generates an agent having a biological activity in vivo.
- Molecules that may be therapeutic agents may be, for example, polypeptides, amino acids, nucleic acids, polynucleotides, nucleosides, steroids, polysaccharides or inorganic compounds. Such molecules may function in any of a variety of ways, including as enzymes, enzyme inhibitors, hormones, receptors, antisense oligonucleotides, catalytic polynucleotides, anti-viral agents, anti-tumor agents, anti-bacterial agents, immunomodulating agents and cytotoxic agents (e.g., radionuclides such as iodine, bromine, lead, rhenium, homium, palladium or copper).
- cytotoxic agents e.g., radionuclides such as iodine, bromine, lead, rhenium, homium, palladium or copper.
- Diagnostic agents include imaging agents such as metals and radioactive agents (e.g., gallium, technetium, indium, strontium, iodine, barium, bromine and phosphorus-containing compounds), contrast agents, dyes (e.g., fluorescent dyes and chromophores) and enzymes that catalyze a colorimetric or fluorometric reaction.
- imaging agents such as metals and radioactive agents (e.g., gallium, technetium, indium, strontium, iodine, barium, bromine and phosphorus-containing compounds), contrast agents, dyes (e.g., fluorescent dyes and chromophores) and enzymes that catalyze a colorimetric or fluorometric reaction.
- therapeutic and diagnostic agents may be attached to a Glycomimetic compound using a variety of techniques such as those described above.
- a Glycomimetic compound may be administered to a patient as described herein.
- Glycomimetic compounds may also be used in vitro, e.g., within a variety of well known cell culture and cell separation methods.
- a Glycomimetic compound may be immobilized on a solid support (such as linked to the interior surface of a tissue culture plate or other cell culture support) for use in immobilizing Pseudomonas bacteria or their products for screens, assays and growth in culture.
- Such linkage may be performed by any suitable technique, such as the methods described above, as well as other standard techniques.
- Glycomimetic compounds may also be used to facilitate cell identification and sorting in vitro, permitting the selection of such bacterial cells.
- the Glycomimetic compound(s) for use in such methods is linked to a diagnostic agent which is a detectable marker.
- Suitable markers are well known in the art and include radionuclides, luminescent groups, fluorescent groups, enzymes, dyes, constant immunoglobulin domains and biotin.
- a Glycomimetic compound linked to a fluorescent marker such as fluorescein
- FACS fluorescence activated cell sorting
- wash steps may be added to a method. For example, subsequent to contacting a sample with a Glycomimetic compound but prior to detection of the compound, the sample may be washed (i.e., contacted with a fluid and then removal of the fluid in order to remove unbound Glycomimetic compound). Alternatively, or in addition, a wash step may be added during the detection process.
- a Glycomimetic compound possesses a marker (a diagnostic agent) that can bind to a substance that is detectable, it may be desirable to wash the sample subsequent to contacting the sample with a detectable substance, but prior to the detection.
- detecting the compound (or agent) in the sample includes detecting the compound (or agent) while it is bound to the sample, or detecting the compound (or agent) which was bound to the sample but after it has been separated from the sample.
- TLC Thin-layer chromatography
- Triethylamine (6.8 L, 48.7 mol) was added to a solution of B2-1 (1 kg, 6.1 mol) and DMAP (74 g, 0.61 mol) in CH 2 CI 2 (12 L), followed by addition Of Ac 2 O (3.46 L, 36.6 mol) at 0-1O 0 C.
- the reaction was stirred at room temperature oversight and then quenched with water (25 L). The layers were separated. The organic phase was washed with water (25 L), saturated aqueous NaHCO 3 (2 x 10 L), and brine (10 L), dried over MgSO 4 , and concentrated to provide crude B2-2 (2.1 kg, quantitative).
- the catalyst was filtered off through a pad overnight at room temperature.
- the catalyst was filtered off through a pad of Celite, the filter pad was washed with ethyl acetate, and the combined filtrate was concentrated.
- Part 2 Compound 2 (11 g, 19.4 mmol) was dissolved in anhydrous CH 2 CI 2 (80 mL), followed by addition of Et 4 NBr (dried at 200 0 C for 2 h under N 2 ; 6.1 g, 29 mmol), anhydrous DMF (50 mL), and molecular sieves (4 A powder, dried; 12 g). After the reaction mixture had been stirred at room temperature for 30 min, the solution from part 1 was added. The reaction mixture was stirred for 40 h at room temperature and then diluted with EtOAc (100 ml_) and filtered through a pad of Celite.
- Tetrabutylammonium bromide (3.65 g, 7.91 mmol) and allyl bromide (1.6 mL, 18.1 mmol) were added.
- the reaction mixture was heated to reflux for 4 h, cooled and then concentrated.
- the residue was purified by chromatography on silica gel eluted with EtOAc/CH 2 CI 2 (7:3) to give 5 (6.4 g, 67% over two steps).
- microtiter plate (plate 1) are coated with PA-IL (Sigma-Aldrich, St. Louis, MO) by incubation for 2 hrs at 37°C. The wells are then blocked for 2 hrs by the addition of 1% bovine serum albumin
- BSA BSA diluted in TBS-Ca (50 mM TrisHCI, 150 mM NaCl, 2 mM CaCI 2 pH 7.4) mixed 1: 1 v/v with Stabilcoat (Surmodics, Eden Prairie, MN).
- Stabilcoat Surmodics, Eden Prairie, MN
- test antagonists are serial diluted in 1% BSA in TBS-Ca /Stabilcoat (60 ⁇ l/well).
- Preformed conjugates of ⁇ -galactose-PAA-biotin (GlycoTech Corp, Gaithersburg, MD) mixed with streptavidin-HRP (KPL Labs, Gaithersburg, MD) are added to each well of plate 2 (60 ⁇ l/well of 2 ⁇ g/ml). Plate 1 is then washed with TBS-Ca and 100 ⁇ l/well are transferred from plate 2 to plate 1. After incubation at room temperature for 2 hrs, plate 1 is washed and 100 ⁇ l of TMB reagent (KPL Labs, Gaithersburg, MD) is added to each well. After incubation for 5 minutes at room temperature, the reaction is stopped by adding 100 ⁇ l/well of IM H 3 PO 4 and the absorbance of light at 450 nm is determined by a microtiter plate reader.
- a microtiter plate (plate 1) are coated with PA-IIL (Dr. Wimmerova, Masaryk University, Brno, Czech Republic) by incubation for 2 hrs at 37°C. The wells are then blocked for 2 hrs by the addition of 1% bovine serum albumin (BSA) diluted in TBS-Ca (50 mM TrisHCI, 150 mM NaCI, 2 mM CaCI 2 pH 7.4) mixed 1 : 1 v/v with Stabilcoat (Surmodics, Eden Prairie, MN). In a second low-binding round-bottom microtiter plate (plate 2), test antagonists are serial diluted in 1% BSA in TBS-Ca /Stabilcoat (60 ⁇ l/well).
- BSA bovine serum albumin
- Preformed conjugates of fucose-PAA-biotin (GlycoTech Corp, Gaithersburg, MD) mixed with streptavidin-HRP (KPL Labs, Gaithersburg, MD) are added to each well of plate 2 (60 ⁇ l/well of 2 ⁇ g/ml). Plate 1 is then washed with TBS-Ca and 100 ⁇ l/well are transferred from plate 2 to plate 1. After incubation at room temperature for 2 hrs, plate 1 is washed and 100 ⁇ l of TMB reagent (KPL Labs, Gaithersburg, MD) is added to each well. After incubation for 5 minutes at room temperature, the reaction is stopped by adding 100 ⁇ l/well of IM H 3 PO 4 and the absorbance of light at 450nm is determined by a microtiter plate reader.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES06801019T ES2375979T3 (en) | 2005-08-09 | 2006-08-08 | GLICOMIMETIC INHIBITORS OF PA-IL LECTIN, PA-IIL LECTIN OR BOTH LECTINES OF PSEUDOMONES. |
EP06801019A EP1928892B1 (en) | 2005-08-09 | 2006-08-08 | Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas |
AT06801019T ATE528311T1 (en) | 2005-08-09 | 2006-08-08 | GLYCOMIMETIC INHIBITORS OF PA-IL-LECTIN, PA-IIL-LECTIN OR BOTH LECTINS FROM PSEUDOMONAS |
JP2008526154A JP5175190B2 (en) | 2005-08-09 | 2006-08-08 | Pseudomonas-derived PA-IL lectin, PA-IIL lectin or a glycomimetic inhibitor of both lectins |
CA2618638A CA2618638C (en) | 2005-08-09 | 2006-08-08 | Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas |
DK06801019.8T DK1928892T3 (en) | 2005-08-09 | 2006-08-08 | Glycomimetic inhibitors of PA-IL lectin PA-IIL lectin or both pseudomonas lectins |
CN200680036323XA CN101291946B (en) | 2005-08-09 | 2006-08-08 | Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas |
AU2006280101A AU2006280101B2 (en) | 2005-08-09 | 2006-08-08 | Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70654605P | 2005-08-09 | 2005-08-09 | |
US60/706,546 | 2005-08-09 | ||
US81019006P | 2006-06-01 | 2006-06-01 | |
US60/810,190 | 2006-06-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007021721A2 true WO2007021721A2 (en) | 2007-02-22 |
WO2007021721A3 WO2007021721A3 (en) | 2007-04-26 |
Family
ID=37600887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/030993 WO2007021721A2 (en) | 2005-08-09 | 2006-08-08 | Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas |
Country Status (10)
Country | Link |
---|---|
US (3) | US7517980B2 (en) |
EP (1) | EP1928892B1 (en) |
JP (2) | JP5175190B2 (en) |
CN (1) | CN101291946B (en) |
AT (1) | ATE528311T1 (en) |
AU (1) | AU2006280101B2 (en) |
CA (1) | CA2618638C (en) |
DK (1) | DK1928892T3 (en) |
ES (1) | ES2375979T3 (en) |
WO (1) | WO2007021721A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007143052A1 (en) * | 2006-06-01 | 2007-12-13 | Glycomimetics, Inc. | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas |
WO2012076934A1 (en) | 2010-12-10 | 2012-06-14 | Centre National De La Recherche Scientifique (Cnrs) | Glycomimetic compounds as anti-infectious against pathogens lectins |
EP2650289A1 (en) * | 2012-04-10 | 2013-10-16 | Universität Konstanz | Glycomimetics as pseudomonas Aeruginosa lectin inhibitors |
KR101492720B1 (en) * | 2013-05-23 | 2015-02-12 | 경상대학교산학협력단 | Antibiotic composition comprising 2-bromoalkanoic acids |
WO2017127422A1 (en) * | 2016-01-22 | 2017-07-27 | Glycomimetics, Inc. | Glycomimetic inhibitors of pa-il and pa-iil lectins |
US9796745B2 (en) | 2011-12-22 | 2017-10-24 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
US9867841B2 (en) | 2012-12-07 | 2018-01-16 | Glycomimetics, Inc. | Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells |
US10519181B2 (en) | 2014-12-03 | 2019-12-31 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
US11072625B2 (en) | 2016-10-07 | 2021-07-27 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
US11197877B2 (en) | 2017-03-15 | 2021-12-14 | Glycomimetics. Inc. | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
US11548908B2 (en) | 2017-12-29 | 2023-01-10 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
US11707474B2 (en) | 2018-03-05 | 2023-07-25 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
US9096880B2 (en) * | 2013-05-15 | 2015-08-04 | National Tsing Hua University | Solubility enhancing peptide and use thereof |
CN103342725B (en) * | 2013-07-26 | 2016-09-14 | 济南尚博生物科技有限公司 | A kind of process for separation and purification of β end group thio glycoside compound |
CN105017341B (en) * | 2014-04-22 | 2018-05-15 | 华东师范大学 | - half lactotetraose of sulphation rock algae and its preparation method and application |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
EP3902797A1 (en) | 2018-12-27 | 2021-11-03 | GlycoMimetics, Inc. | Galectin-3 inhibiting c-glycosides |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4471057A (en) * | 1981-06-30 | 1984-09-11 | The Wistar Institute | Detection of colorectal carcinoma |
DK17885D0 (en) * | 1985-01-14 | 1985-01-14 | Karlsson Karl Anders | ANTIVIRAL AGENT |
US4876199A (en) * | 1985-04-04 | 1989-10-24 | Fred Hutchinson Cancer Research Center | Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain |
US4851511A (en) * | 1986-01-30 | 1989-07-25 | Fred Hutchinson Cancer Research Center | Monoclonal antibody that specifically binds to disialosyl Lea |
US4925796A (en) * | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
DE3787403D1 (en) * | 1986-05-09 | 1993-10-21 | Pulverer Gerhard | Use of specific monosaccharides for the manufacture of a medicament for the prevention of metastases of malignant tumors. |
US5538724A (en) * | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
US5464778A (en) * | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
US6033665A (en) * | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
US6001988A (en) | 1990-06-11 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US6280932B1 (en) * | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
US5576305A (en) * | 1990-06-15 | 1996-11-19 | Cytel Corporation | Intercellular adhesion mediators |
US5753631A (en) * | 1990-06-15 | 1998-05-19 | Cytel Corporation | Intercellular adhesion mediators |
US6391857B1 (en) * | 1990-06-18 | 2002-05-21 | Stanford University | Methods and compositions for endothelial binding |
US6387884B1 (en) * | 1990-06-18 | 2002-05-14 | Stanford University | Leukocyte homing modulation |
US5211937A (en) * | 1990-07-30 | 1993-05-18 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5143712A (en) * | 1990-07-30 | 1992-09-01 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5648344A (en) * | 1990-07-30 | 1997-07-15 | Glycomed Incorporated | Methods of treating inflammation using selection binding compounds |
US5789573A (en) * | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
WO1992009293A1 (en) * | 1990-11-23 | 1992-06-11 | The General Hospital Corporation | Inhibition of cell adhesion protein-carbohydrate interactions |
US5151360A (en) * | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
US6309639B1 (en) * | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
US6124267A (en) * | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
US6121233A (en) * | 1991-04-19 | 2000-09-19 | John L. Magnani | Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules |
ES2201049T3 (en) * | 1991-05-06 | 2004-03-16 | Genentech, Inc. | A BINDING OF SELECTINE. |
US5318890A (en) * | 1991-05-06 | 1994-06-07 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
US5580858A (en) | 1991-06-10 | 1996-12-03 | Alberta Research Council | Immunosuppressive and tolerogenic modified Lewisx compounds |
US5646123A (en) * | 1991-06-10 | 1997-07-08 | Alberta Research Council | Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen |
US5352670A (en) * | 1991-06-10 | 1994-10-04 | Alberta Research Council | Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides |
CA2118695A1 (en) * | 1991-09-10 | 1993-03-18 | George A. Heavner | Peptide inhibitors of inflammation mediated by selectins |
US5268364A (en) | 1991-12-12 | 1993-12-07 | The Biomembrane Institute | Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification |
WO1994004568A1 (en) * | 1991-12-18 | 1994-03-03 | Centocor, Inc. | Peptide inhibitors of inflammation mediated by selectins |
US5591835A (en) * | 1992-06-29 | 1997-01-07 | Glycomed Incorporated | Substituted lactose derivatives |
CA2100412A1 (en) * | 1992-07-15 | 1994-01-16 | Yutaka Yamada | Glycolipid derivatives |
JPH08503694A (en) * | 1992-09-08 | 1996-04-23 | セントコー・インコーポレーテッド | Peptide-based cell adhesion inhibitor |
US5519008A (en) * | 1992-09-10 | 1996-05-21 | Glycomed Incorporated | Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin) |
AU4859793A (en) | 1992-09-11 | 1994-04-12 | Regents Of The University Of California, The | Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation |
US5695752A (en) | 1992-09-11 | 1997-12-09 | The Regents Of The University Of California | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
US6277975B1 (en) * | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
EP0601417A3 (en) * | 1992-12-11 | 1998-07-01 | Hoechst Aktiengesellschaft | Physiologically compatible and degradable polymer-based carbohydrate receptor blockers, a method for their preparation and their use |
WO1994014836A1 (en) * | 1992-12-18 | 1994-07-07 | Centocor, Inc. | Peptide inhibitors of selectin binding |
AU678429B2 (en) * | 1992-12-29 | 1997-05-29 | Genentech Inc. | Treatment of inflammatory bowel disease with IFN-gamma inhibitors |
US5412123A (en) * | 1993-02-08 | 1995-05-02 | Glycomed Incorporated | Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system |
EP0687684A4 (en) * | 1993-03-04 | 1998-03-04 | Kanto Ishi Pharma Co Ltd | Lewis-associated compound, process for producing the same, and anti-inflammatory |
US5527890A (en) * | 1993-04-16 | 1996-06-18 | Glycomed Incorporated | Derivatives of triterpenoid acids and uses thereof |
NZ266972A (en) * | 1993-05-14 | 1997-08-22 | Cytel Corp | Sialyl lewis analogues, compounds, preparation, and pharmaceutical compositions |
US5527785A (en) * | 1993-05-14 | 1996-06-18 | The Regents Of The University Of California | Selectin receptor modulating compositions |
US5854218A (en) | 1993-05-14 | 1998-12-29 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
US5811404A (en) * | 1993-05-14 | 1998-09-22 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
US5976540A (en) | 1993-05-17 | 1999-11-02 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
WO1994026786A1 (en) * | 1993-05-17 | 1994-11-24 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5646248A (en) * | 1993-06-08 | 1997-07-08 | La Jolla Cancer Research Foundation | E-selection binding soluble lamp-1 polypeptide |
US5789385A (en) * | 1993-06-16 | 1998-08-04 | Glycomed Incorporated | Sialyl Lewisx mimetics containing phenyl backbones |
US5837689A (en) | 1993-06-16 | 1998-11-17 | Glycomed Incorporated | Sialyl lewis-x mimetics containing naphthyl backbones |
US5750508A (en) * | 1993-06-16 | 1998-05-12 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5658880A (en) * | 1993-06-16 | 1997-08-19 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5679321A (en) * | 1993-06-17 | 1997-10-21 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
DK76193D0 (en) * | 1993-06-25 | 1993-06-25 | Astra Ab | CARBOHYDRATE DERIVATIVES |
US5559103A (en) * | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
US5508387A (en) * | 1993-08-04 | 1996-04-16 | Glycomed Incorporated | Selectin binding glycopeptides |
WO1995005830A1 (en) * | 1993-08-20 | 1995-03-02 | The Regents Of The University Of California | Polyanion anti-inflammatory agents |
US5464815A (en) * | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
WO1995010296A1 (en) * | 1993-10-12 | 1995-04-20 | Glycomed Incorporated | A library of glyco-peptides useful for identification of cell adhesion inhibitors |
US5783693A (en) | 1993-11-19 | 1998-07-21 | The Regents Of The University Of California | Methods for synthesizing sulfated disaccharide inhibitors of selectins |
WO1995014787A1 (en) * | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
US5663151A (en) * | 1994-03-04 | 1997-09-02 | Bristol-Myers Squibb Company | Sulfated α-glycolipid derivatives as cell adhesion inhibitors |
EP0671409A3 (en) | 1994-03-11 | 1996-06-12 | Hoechst Ag | Malonic acid derivatives having anti-adhesive properties. |
DE4408248A1 (en) * | 1994-03-11 | 1995-09-14 | Hoechst Ag | Physiologically acceptable and physiologically degradable carbohydrate mimetics, process for their preparation and their use |
US5444050A (en) * | 1994-04-29 | 1995-08-22 | Texas Biotechnology Corporation | Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa |
HUT77345A (en) * | 1994-04-29 | 1998-03-30 | Texas Biotechnology Corporation | Mannopyranosyloxy biphenyl derivatives capable of inhibiting the binding of e-selectin,p-selectin or l-selectin to sialyl-lewis x or sialyl-lewis a and pharmaceutical compositions containing them |
US5486536A (en) * | 1994-08-15 | 1996-01-23 | The Regents Of The University Of Michigan | Sulfatides as anti-inflammatory compounds |
JPH0899989A (en) | 1994-09-30 | 1996-04-16 | Akira Hasegawa | New glycolipid derivative and intermediate for its production |
DE4436164A1 (en) * | 1994-10-10 | 1996-04-11 | Hoechst Ag | New conjugates of tetra:carbohydrate and amide-linked peptide or dye etc. |
US5686426A (en) * | 1994-11-17 | 1997-11-11 | Bristol-Myers Squibb Company | Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors |
US6492332B1 (en) | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
US5639734A (en) * | 1994-12-20 | 1997-06-17 | Esko; Jeffrey D. | Disaccharide inflammation inhibitors and uses thereof |
US20020040008A1 (en) * | 1995-01-24 | 2002-04-04 | Wagner Denisa D. | Method for treating and preventing atherosclerosis |
US5736533A (en) | 1995-06-07 | 1998-04-07 | Neose Technologies, Inc. | Bacterial inhibition with an oligosaccharide compound |
GB9515098D0 (en) * | 1995-07-21 | 1995-09-20 | Bp Chem Int Ltd | Catalyst compositions |
US5876715A (en) * | 1995-08-17 | 1999-03-02 | The Biomembrane Institute | Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof |
DE19532902A1 (en) * | 1995-09-06 | 1997-03-13 | Hoechst Ag | Novel glycomimetics as selectin antagonists and anti-inflammatory drugs made from them |
DE19537334A1 (en) * | 1995-10-09 | 1997-04-10 | Hoechst Ag | New piperidine carboxylic acid and pyrrolidine carboxylic acid derivs. |
US5919769A (en) * | 1995-10-26 | 1999-07-06 | Kanebo, Ltd | Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same |
US5747463A (en) * | 1995-11-13 | 1998-05-05 | Bristol-Myers Squibb Company | Malonate derivatives of glycolipids as cell adhesion inhibitors |
DE19602355A1 (en) * | 1996-01-24 | 1997-07-31 | Hoechst Ag | Multiple fucosylated dicarboxylic acids with anti-adhesive properties |
WO1997028173A1 (en) * | 1996-01-30 | 1997-08-07 | Novartis Ag | SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES |
US6187754B1 (en) * | 1996-01-30 | 2001-02-13 | Glycotech Corp. | Sialyl-Lewisa and sialyl-Lewisx epitode analogues |
US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
WO1997031625A1 (en) | 1996-03-01 | 1997-09-04 | The Regents Of The University Of California | Inhibition of selectin binding |
US5654412A (en) * | 1996-05-29 | 1997-08-05 | Glycomed Incorporated | Processes for the synthesis of sialyl Lewisx compounds |
CA2197058A1 (en) | 1996-06-05 | 1997-12-06 | Avery B. Nathens | Anti-inflammatory agent |
US5919768A (en) * | 1996-06-26 | 1999-07-06 | Texas Biotechnology Corporation | Di- and trivalent small molecule selectin inhibitors |
US5830871A (en) | 1996-10-28 | 1998-11-03 | The Scripps Research Institute | Inhibitors of E-, P- and L-selectin binding |
GB9618520D0 (en) * | 1996-09-05 | 1996-10-16 | Chiroscience Ltd | Compounds and their therapeutic use |
US6110897A (en) * | 1996-10-10 | 2000-08-29 | Glycorex Ab | Antiinflammatory cell adhesion inhibitors |
US6235309B1 (en) * | 1997-02-28 | 2001-05-22 | The Regents Of The University Of California | Inhibition of cell-cell binding by lipid assemblies |
US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
SE9701127D0 (en) * | 1997-03-26 | 1997-03-26 | Karolinska Innovations Ab | Antigenic fusion protein carrying GALal, 3GAL epitopes |
US5916910A (en) * | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
US6193973B1 (en) * | 1997-08-22 | 2001-02-27 | B. David Tuttle | Dietary supplement for boosting energy and increasing muscular strength |
US5948628A (en) * | 1997-09-05 | 1999-09-07 | The Board Of Regents Of The University Of Oklahoma | Methods of screening for compounds which mimic galectin-1 |
WO1999043353A2 (en) | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
US6265192B1 (en) | 1998-03-20 | 2001-07-24 | The Regents Of The University Of California | Glycosly sulfortransferase-3 |
US6365365B1 (en) | 1998-03-20 | 2002-04-02 | The Regents Of The University Of California | Method of determining whether an agent modulates glycosyl sulfotransferase-3 |
US6037333A (en) * | 1998-05-07 | 2000-03-14 | Trustees Of Tufts College | Microbe-inhibiting compositions |
DE69934890D1 (en) * | 1998-06-16 | 2007-03-08 | Univ Oklahoma | GLYCOSULFOPEPTIDES AND PROCESS FOR THEIR PRODUCTION AND THEIR USE |
US6503885B1 (en) * | 1998-09-21 | 2003-01-07 | Otsuka Pharmaceutical Co., Ltd. | Carboxymethylgalactose derivatives |
RU2227752C2 (en) | 1998-11-12 | 2004-04-27 | Новолитикс Инк. | Method for overlapping circulation and compositions for their realization |
CA2408883A1 (en) * | 2000-05-19 | 2001-11-29 | The Center For Blood Research, Inc. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
US20020132220A1 (en) * | 2000-12-27 | 2002-09-19 | Berens Kurt L. | Use of selectin antagonists in organ preservation solutions |
US7087212B2 (en) * | 2001-08-17 | 2006-08-08 | Mallinckrodt, Inc | Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
JP2006515306A (en) * | 2002-12-20 | 2006-05-25 | グリコミメティクス, インコーポレイテッド | Oligosaccharides and conjugates thereof for the treatment of Pseudomonas bacterial infections |
US20070066232A1 (en) * | 2005-09-22 | 2007-03-22 | Black Peter J | Pilot grouping and route protocols in multi-carrier communication systems |
-
2006
- 2006-08-08 JP JP2008526154A patent/JP5175190B2/en active Active
- 2006-08-08 EP EP06801019A patent/EP1928892B1/en active Active
- 2006-08-08 DK DK06801019.8T patent/DK1928892T3/en active
- 2006-08-08 US US11/501,464 patent/US7517980B2/en active Active
- 2006-08-08 ES ES06801019T patent/ES2375979T3/en active Active
- 2006-08-08 CA CA2618638A patent/CA2618638C/en active Active
- 2006-08-08 AU AU2006280101A patent/AU2006280101B2/en active Active
- 2006-08-08 CN CN200680036323XA patent/CN101291946B/en active Active
- 2006-08-08 AT AT06801019T patent/ATE528311T1/en not_active IP Right Cessation
- 2006-08-08 WO PCT/US2006/030993 patent/WO2007021721A2/en active Application Filing
-
2009
- 2009-02-13 US US12/370,826 patent/US8258290B2/en active Active
-
2012
- 2012-08-03 US US13/566,522 patent/US20120329755A1/en not_active Abandoned
- 2012-12-06 JP JP2012267339A patent/JP2013049718A/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
None |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007143052A1 (en) * | 2006-06-01 | 2007-12-13 | Glycomimetics, Inc. | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas |
WO2012076934A1 (en) | 2010-12-10 | 2012-06-14 | Centre National De La Recherche Scientifique (Cnrs) | Glycomimetic compounds as anti-infectious against pathogens lectins |
US9796745B2 (en) | 2011-12-22 | 2017-10-24 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
US11332491B2 (en) | 2011-12-22 | 2022-05-17 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
US10766916B2 (en) | 2011-12-22 | 2020-09-08 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
US10526361B2 (en) | 2011-12-22 | 2020-01-07 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
US9371351B2 (en) | 2012-04-10 | 2016-06-21 | Universität Konstanz | Glycomimetics as Pseudomonas aeruginosa lectin inhibitors |
WO2013152848A1 (en) * | 2012-04-10 | 2013-10-17 | Universität Konstanz | Glycomimetics as pseudomonas aeruginosa lectin inhibitors |
EP2650289A1 (en) * | 2012-04-10 | 2013-10-16 | Universität Konstanz | Glycomimetics as pseudomonas Aeruginosa lectin inhibitors |
US9867841B2 (en) | 2012-12-07 | 2018-01-16 | Glycomimetics, Inc. | Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells |
KR101492720B1 (en) * | 2013-05-23 | 2015-02-12 | 경상대학교산학협력단 | Antibiotic composition comprising 2-bromoalkanoic acids |
US10519181B2 (en) | 2014-12-03 | 2019-12-31 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
WO2017127422A1 (en) * | 2016-01-22 | 2017-07-27 | Glycomimetics, Inc. | Glycomimetic inhibitors of pa-il and pa-iil lectins |
US11045485B2 (en) | 2016-01-22 | 2021-06-29 | Glycomimetics, Inc. | Glycomimetic inhibitors of PA-IL and PA-IIL lectins |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
US11072625B2 (en) | 2016-10-07 | 2021-07-27 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
US11780873B2 (en) | 2016-10-07 | 2023-10-10 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
US11197877B2 (en) | 2017-03-15 | 2021-12-14 | Glycomimetics. Inc. | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists |
US11878026B2 (en) | 2017-03-15 | 2024-01-23 | Glycomimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
US11548908B2 (en) | 2017-12-29 | 2023-01-10 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
US11707474B2 (en) | 2018-03-05 | 2023-07-25 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
Also Published As
Publication number | Publication date |
---|---|
JP2009504660A (en) | 2009-02-05 |
JP5175190B2 (en) | 2013-04-03 |
US7517980B2 (en) | 2009-04-14 |
CN101291946B (en) | 2011-06-29 |
US8258290B2 (en) | 2012-09-04 |
CN101291946A (en) | 2008-10-22 |
ES2375979T3 (en) | 2012-03-07 |
EP1928892B1 (en) | 2011-10-12 |
US20070037775A1 (en) | 2007-02-15 |
ATE528311T1 (en) | 2011-10-15 |
US20100041626A1 (en) | 2010-02-18 |
CA2618638A1 (en) | 2007-02-22 |
CA2618638C (en) | 2014-03-11 |
US20120329755A1 (en) | 2012-12-27 |
DK1928892T3 (en) | 2012-01-30 |
JP2013049718A (en) | 2013-03-14 |
WO2007021721A3 (en) | 2007-04-26 |
EP1928892A2 (en) | 2008-06-11 |
AU2006280101A1 (en) | 2007-02-22 |
AU2006280101B2 (en) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7517980B2 (en) | Glycomimetric inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas | |
JP5183010B2 (en) | Compounds and methods for inhibiting selectin-mediated functions | |
US20050187171A1 (en) | Glycomimetic antagonists for both E-and P-selectins | |
WO2007143052A1 (en) | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas | |
WO2006127906A1 (en) | Heterobifunctional compounds for selectin inhibition | |
US20040219158A1 (en) | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria | |
US20050164982A1 (en) | Specific antagonist for both E- and P-selectins | |
JP2006515306A (en) | Oligosaccharides and conjugates thereof for the treatment of Pseudomonas bacterial infections | |
US11045485B2 (en) | Glycomimetic inhibitors of PA-IL and PA-IIL lectins | |
JP2002514652A (en) | 1-galactose derivative | |
WO1997002278A1 (en) | Sugar chain derivatives and process for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680036323.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2618638 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008526154 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006280101 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006801019 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006280101 Country of ref document: AU Date of ref document: 20060808 Kind code of ref document: A |